AR and prostate carcinoma: Indeed, steroid hormone receptors including androgen receptor (AR) are members of a superfamily of ligand-activated transcription factors that are potentially oncogenic in gliomas as has been proposed by other researchers (17, 18) and has been confirmed in prostate cancer (19).